Video

Dr. Pal on CRISPR-Based Technology in RCC

Sumanta Kumar Pal, MD, discusses potential developments with vaccines and CRISPR/Cas9 technology coming down the pipeline in renal cell carcinoma.

Sumanta Kumar Pal, MD, an associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, and medical oncologist at City of Hope, discusses potential developments with vaccines and CRISPR/Cas9 technology coming down the pipeline in renal cell carcinoma (RCC).

Immunotherapy, particularly CAR T-cell therapy, has been challenging to develop in solid tumors, leading to further exploration with novel techniques, Pal says. More recently, Pal has been working with CRISPR to develop anti-CD70 CAR T cells.

Targeting a specific antigen has always been a challenge in RCC, Pal says. With CRISPR, a unique target has been identified and appears to have potential benefit in a large proportion of RCC patients.

Related Videos
Dr Fakih on the FDA Approval of Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC
Al Malki
Ian Krop MD, PhD
Timothy S. Fenske, MD, MS
Ignacio Garrido-Laguna, MD, PhD, MBA
Marwan G. Fakih, MD
Dr Alderuccio on Loncastuximab Tesirine With Rituximab in R/R Follicular Lymphoma
Dr Cascone on Evaluating Neoadjuvant Durvalumab-Based Regimens in Resectable NSCLC
Werutsky
Dr Sekkeres on the Association Between Smoking and Disease Progression in MDS